CN104411697B - 樟脑磺酸盐 - Google Patents

樟脑磺酸盐 Download PDF

Info

Publication number
CN104411697B
CN104411697B CN201380033030.6A CN201380033030A CN104411697B CN 104411697 B CN104411697 B CN 104411697B CN 201380033030 A CN201380033030 A CN 201380033030A CN 104411697 B CN104411697 B CN 104411697B
Authority
CN
China
Prior art keywords
disease
alzheimer
indenes
dementia
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380033030.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104411697A (zh
Inventor
M·H·博林
C·R·斯图尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN201610570484.2A priority Critical patent/CN106279102A/zh
Publication of CN104411697A publication Critical patent/CN104411697A/zh
Application granted granted Critical
Publication of CN104411697B publication Critical patent/CN104411697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380033030.6A 2012-06-21 2013-06-20 樟脑磺酸盐 Active CN104411697B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610570484.2A CN106279102A (zh) 2012-06-21 2013-06-20 樟脑磺酸盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
US61/662,592 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610570484.2A Division CN106279102A (zh) 2012-06-21 2013-06-20 樟脑磺酸盐

Publications (2)

Publication Number Publication Date
CN104411697A CN104411697A (zh) 2015-03-11
CN104411697B true CN104411697B (zh) 2016-08-10

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380033030.6A Active CN104411697B (zh) 2012-06-21 2013-06-20 樟脑磺酸盐
CN201610570484.2A Pending CN106279102A (zh) 2012-06-21 2013-06-20 樟脑磺酸盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610570484.2A Pending CN106279102A (zh) 2012-06-21 2013-06-20 樟脑磺酸盐

Country Status (42)

Country Link
US (1) US10548882B2 (cg-RX-API-DMAC7.html)
EP (2) EP3064494A1 (cg-RX-API-DMAC7.html)
JP (2) JP2015520221A (cg-RX-API-DMAC7.html)
KR (1) KR102123708B1 (cg-RX-API-DMAC7.html)
CN (2) CN104411697B (cg-RX-API-DMAC7.html)
AP (2) AP2017009693A0 (cg-RX-API-DMAC7.html)
AR (2) AR091495A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013279109B2 (cg-RX-API-DMAC7.html)
BR (2) BR122016014302B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875589C (cg-RX-API-DMAC7.html)
CL (1) CL2014003374A1 (cg-RX-API-DMAC7.html)
CO (1) CO7151486A2 (cg-RX-API-DMAC7.html)
CR (2) CR20140571A (cg-RX-API-DMAC7.html)
CY (1) CY1119505T1 (cg-RX-API-DMAC7.html)
DK (1) DK2864316T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000268A (cg-RX-API-DMAC7.html)
EC (1) ECSP14032215A (cg-RX-API-DMAC7.html)
ES (1) ES2618939T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170359T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033376T2 (cg-RX-API-DMAC7.html)
IL (1) IL236131A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10088A (cg-RX-API-DMAC7.html)
LT (1) LT2864316T (cg-RX-API-DMAC7.html)
MA (2) MA39259B1 (cg-RX-API-DMAC7.html)
ME (1) ME02633B (cg-RX-API-DMAC7.html)
MX (1) MX354214B (cg-RX-API-DMAC7.html)
NI (1) NI201400146A (cg-RX-API-DMAC7.html)
NZ (2) NZ727045A (cg-RX-API-DMAC7.html)
PE (1) PE20150670A1 (cg-RX-API-DMAC7.html)
PH (2) PH12014502803B1 (cg-RX-API-DMAC7.html)
PL (1) PL2864316T3 (cg-RX-API-DMAC7.html)
PT (1) PT2864316T (cg-RX-API-DMAC7.html)
RS (1) RS55815B1 (cg-RX-API-DMAC7.html)
RU (1) RU2638175C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201407934UA (cg-RX-API-DMAC7.html)
SI (1) SI2864316T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700142T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000491A1 (cg-RX-API-DMAC7.html)
TW (2) TWI639591B (cg-RX-API-DMAC7.html)
UA (1) UA114196C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013190302A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500408B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
UY36347A (es) 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
CA3017418A1 (en) * 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
WO2020183021A1 (en) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105179A2 (en) * 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011002408A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia
WO2012087237A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as bace inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7915424B2 (en) 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
BRPI0612072A2 (pt) 2005-06-14 2010-10-19 Schering Corp inibidores da aspartil protease
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
CA2633992A1 (en) 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
US20090325993A1 (en) 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
KR20100017573A (ko) 2007-05-07 2010-02-16 쉐링 코포레이션 감마 세크레타제 조정인자
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2010030954A1 (en) 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105179A2 (en) * 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011002408A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia
WO2012087237A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as bace inhibitors

Also Published As

Publication number Publication date
RU2014148305A (ru) 2016-08-10
JP2018104448A (ja) 2018-07-05
PE20150670A1 (es) 2015-06-03
CN104411697A (zh) 2015-03-11
PT2864316T (pt) 2017-02-24
JP6509393B2 (ja) 2019-05-08
KR102123708B1 (ko) 2020-06-16
CR20160202A (es) 2016-07-26
LT2864316T (lt) 2017-03-27
AR091495A1 (es) 2015-02-11
UA114196C2 (uk) 2017-05-10
MA39259A1 (fr) 2017-12-29
BR112014031531B1 (pt) 2022-08-02
CR20140571A (es) 2015-02-04
MA37666A1 (fr) 2016-04-29
PH12016500498A1 (en) 2017-04-10
SG11201407934UA (en) 2015-01-29
CY1119505T1 (el) 2018-03-07
CA2875589C (en) 2020-08-25
IL236131A0 (en) 2015-02-01
MA37666B1 (fr) 2016-12-30
PH12014502803A1 (en) 2015-02-23
MX2014014709A (es) 2015-03-04
DOP2014000268A (es) 2015-04-15
CL2014003374A1 (es) 2015-02-27
EP2864316B1 (en) 2016-12-14
ME02633B (me) 2017-06-20
TN2014000491A1 (en) 2016-03-30
HRP20170359T1 (hr) 2017-05-05
CO7151486A2 (es) 2014-12-29
TWI639591B (zh) 2018-11-01
NZ727045A (en) 2018-06-29
ES2618939T3 (es) 2017-06-22
AR105176A2 (es) 2017-09-13
HK1206349A1 (en) 2016-01-08
PH12014502803B1 (en) 2015-02-23
MX354214B (es) 2018-02-19
AU2017254965B2 (en) 2019-05-09
CN106279102A (zh) 2017-01-04
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
KR20150023388A (ko) 2015-03-05
NZ702742A (en) 2016-12-23
MA39259B1 (fr) 2018-09-28
PL2864316T3 (pl) 2017-09-29
DK2864316T3 (en) 2017-03-20
TW201406745A (zh) 2014-02-16
BR122016014302B1 (pt) 2022-08-23
IN2014DN10088A (cg-RX-API-DMAC7.html) 2015-08-21
HUE033376T2 (en) 2017-11-28
TWI588140B (zh) 2017-06-21
RS55815B1 (sr) 2017-08-31
EP2864316A1 (en) 2015-04-29
SI2864316T1 (sl) 2017-04-26
ECSP14032215A (es) 2015-12-31
AU2013279109B2 (en) 2017-08-31
AU2017254965A1 (en) 2017-11-23
WO2013190302A1 (en) 2013-12-27
AP2014008137A0 (en) 2014-12-31
AP2017009693A0 (en) 2017-01-31
JP2015520221A (ja) 2015-07-16
US10548882B2 (en) 2020-02-04
SMT201700142T1 (it) 2017-05-08
BR112014031531A2 (pt) 2017-06-27
US20140031379A1 (en) 2014-01-30
ZA201500408B (en) 2016-10-26
RU2638175C2 (ru) 2017-12-12
NI201400146A (es) 2016-09-21
EP3064494A1 (en) 2016-09-07
TW201730177A (zh) 2017-09-01
BR122016014302A2 (pt) 2019-08-27

Similar Documents

Publication Publication Date Title
CN104411697B (zh) 樟脑磺酸盐
JP5686796B2 (ja) c−Metタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤
US8269012B2 (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
US8263776B2 (en) Inhibitors of c-Met protein kinase
HK1206349B (en) Camsylate salt of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of a[beta]-related pathologies such as e.g. alzheimer's disease
HK1229787A1 (en) A process for the preparation of a camsylate salt ((1s)-(+)-10 camphorsulfonic acid) of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant